Epitalon: AEDG molecular patent — US6727227B1
Vladimir K. Khavinson · 2004 · US6727227B1 · patent family 20219149
Published 2004-04-27.
Reported patent results
Reported findings
Epitalon results vary by species, sex, strain and endpoint; the patent does not demonstrate longer human life.
Multiple animal/fly experiments plus small uncontrolled human examples: 14 patients with age-related conditions and 11 with aspirin-sensitive asthma.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| HEM female flies: average lifespan | 48 ± 1.5 days treated versus 38 ± 1.6 control | A fly experiment, not human survival · p<0.001 |
| LA female flies: average versus maximum lifespan | Average 20 ± 1.3 versus 22 ± 1.0 days; maximum 44 ± 1.9 versus 36 ± 1.9 days | Maximum lifespan improved while average lifespan did not; separate endpoints · · Maximum comparison p<0.05 |
| Human oxidative marker | Superoxide dismutase 0.26 → 0.61 conventional units/mg protein | 14-patient uncontrolled age-related-condition example · p<0.05 before/after |
| Asthma example | Symptoms described as improved, but no essential change in the listed baseline respiratory-function measures, including FEV1 | 11 patients; no placebo group reported |
Many exploratory experiments and small selected human examples do not constitute a longevity trial. Strain/sex-specific neutral or unfavorable averages must not be replaced by maximum-lifespan claims.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The patent claims the defined tetrapeptide Ala-Glu-Asp-Gly, related compositions and proposed uses.
The synthetic peptide differs from Epithalamin extract. Patent geroprotection claims do not demonstrate extension of human lifespan.
- Publication
- US6727227B1 ↗ · 2004-04-27
- Earliest priority / filing
- 1999-05-11 / 2000-01-20
- Original applicant / assignee
- Nostiji "Klinika Instituta Bioregulyatsii Gerontologii" OOO
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 20219149 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
Inventors: Vladimir K. Khavinson.
US6727227B1 · EP1179008B1 · JP3902406B2 · ATE321068T1 · AU769847C · CA2373128C · DE60026826T2 · ES2259998T3 · IL146432A0 · RU2157233C1 · WO2000068255A2
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The synthetic peptide differs from Epithalamin extract. Patent geroprotection claims do not demonstrate extension of human lifespan.
- Many exploratory experiments and small selected human examples do not constitute a longevity trial. Strain/sex-specific neutral or unfavorable averages must not be replaced by maximum-lifespan claims.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20219149. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladimir K. Khavinson. Epitalon: AEDG molecular patent — US6727227B1 US6727227B1 · patent family 20219149 2004.
Molekul research summary: https://molekul.io/research/patent-us6727227b1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry